VFA
AMRX icon

Virtus Fund Advisers’s Amneal Pharmaceuticals AMRX Stock Holding History

Virtus Fund Advisers’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,941
Closed -$21.5K – 101
2023
Q2 		$21.5K Hold
6,941
– – 0.15% 92
2023
Q1 		$9.65K Buy
+6,941
New +$13.8K 0.07% 104

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtus Fund Advisers's AMRX Position: Q3 2023 in Review

Virtus Fund Advisers sold out of Amneal Pharmaceuticals (AMRX) in Q3 2023, closing a stake of 6,941 shares — an estimated $21.5K sold.

Virtus Fund Advisers first reported a position in AMRX in Q1 2023 and held it in 2 quarters. The position peaked at $21.5K in Q2 2023. 144 funds tracked by Wall St. Rank hold AMRX as of Q3 2023.

  • Virtus Fund Advisers reported no remaining Amneal Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Virtus Fund Advisers sold 6,941 Amneal Pharmaceuticals shares in Q3 2023, an estimated $21.5K.
  • Virtus Fund Advisers first reported a position in Amneal Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Virtus Fund Advisers's Amneal Pharmaceuticals position peaked at $21.5K in Q2 2023.
  • 144 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2023.

Based on Virtus Fund Advisers's 13F filing for Q3 2023, filed 8 Nov 2023.